Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-25-059248
Filing Date
2025-06-30
Accepted
2025-06-30 07:31:27
Documents
6
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea0247391-6k_nlspharm.htm 6-K 16130
2 AMENDMENT TO SECURITIES PURCHASE AGREEMENT, DATED JUNE 26, 2025, BETWEEN NLS PHA ea024739101ex99-2_nlspharm.htm EX-99.2 79193
3 FORM OF COMMON WARRANT ea024739101ex99-3_nlspharm.htm EX-99.3 107538
4 SIDE LETTER ea024739101ex99-4_nlspharm.htm EX-99.4 10121
5 PRESS RELEASE TITLED: "NLS PHARMACEUTICS AND KADIMASTEM ANNOUNCE PRICING AND CLO ea024739101ex99-6_nlspharm.htm EX-99.6 18481
6 GRAPHIC ex99-6_001.jpg GRAPHIC 80191
  Complete submission text file 0001213900-25-059248.txt   343091
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 251088757
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)